PLYMOUTH MEETING – November 03, 2026 -- INOVIO (NASDAQ: INO) will present its INO-D001 program for Hemophilia A at the World Federation of Hemophilia New Technology & Gene Therapy (NTGT) Workshop in Montreal on Thursday, Nov. 12, extending its DNA medicine work beyond HPV-related diseases, cancer and infectious diseases.

INOVIO schedules rare disease presentation in New York for Nov. 8

The company will speak at the Soft Bones Third International Scientific Meeting on Hypophosphatasia in New York on Sunday, Nov. 8. Its presentation is titled "Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine."

Montreal workshop session focuses on INO-D001 for Hemophilia A

The Nov. 12 presentation at the WFH NTGT Workshop is dedicated to INO-D001 in Hemophilia A. The two appearances are four days apart, on Nov. 8 and Nov. 12.

INOVIO said abstracts and presentations will be added to its events page if available. It did not disclose data, trial details or development timelines for INO-D001 in the announcement.